Stem Cell Therapies for Blindness due to Corneal, Lens, and Retinal Diseases: A Review

Author(s):  
Vincent Gallicchio

Stem cell therapies are continuing to be researched and implemented to treat a wide range of disorders that result in blindness. Major structures of the eye most prevalently tied to blindness are the cornea, lens, and retina, and specific conditions resulting in blindness includes corneal disease, stromal scarring, cataracts, age-related macular degeneration, retinitis pigmentosa, glaucoma, and diabetic retinopathy. This review covers a detailed description of the structures of the eye, the causes and corresponding disease pathways of each form of corneal, lens, and retinal dysfunction that results in blindness, and the current stem cell sources being researched and implemented, through animal models and clinical trials, to treat blindness. The review evaluates the progress of stem cell research and trials and presents the obstacles that remain to be overcome before stem cell sources to treat blindness can become standard clinical practice.

2021 ◽  
Vol 10 (8) ◽  
pp. 1785
Author(s):  
Tadao Maeda ◽  
Sunao Sugita ◽  
Yasuo Kurimoto ◽  
Masayo Takahashi

Age-related macular degeneration (AMD) is a highly prevalent irreversible impairment in the elderly population worldwide. Stem cell therapies have been considered potentially viable for treating AMD through the direct replacement of degenerated cells or secretion of trophic factors that facilitate the survival of existing cells. Among them, the safety of pluripotent stem cell-derived retinal pigment epithelial (RPE) cell transplantation against AMD, and some hereditary retinal degenerative diseases, has been discussed to a certain extent in clinical studies of RPE cell transplantation. Preparations are in progress for its clinical application. On the other hand, clinical trials using somatic stem cells are also being conducted, though these had controversial outcomes. Retinal regenerative medicine using stem cells is expected to make steady progress toward practical use while new technologies are incorporated from various fields, thereby making the role of ophthalmologists in this field increasingly important.


2013 ◽  
Vol 36 (7) ◽  
pp. 385-395 ◽  
Author(s):  
Amanda-Jayne F. Carr ◽  
Matthew J.K. Smart ◽  
Conor M. Ramsden ◽  
Michael B. Powner ◽  
Lyndon da Cruz ◽  
...  

BMJ Open ◽  
2018 ◽  
Vol 8 (2) ◽  
pp. e019414 ◽  
Author(s):  
Blake Murdoch ◽  
Amy Zarzeczny ◽  
Timothy Caulfield

ObjectiveTo identify the frequency and qualitative characteristics of stem cell-related marketing claims made on websites of clinics featuring common types of complementary and alternative medicine practitioners. The involvement of complementary and alternative medicine practitioners in the marketing of stem cell therapies and stem cell-related interventions is understudied. This research explores the extent to which they are involved and collaborate with medical professionals. This knowledge will help with identifying and evaluating potential policy responses to this growing market.DesignSystematic website analysis.SettingGlobal. US and English-language bias due to methodology.Main outcome measuresRepresentations made on clinic websites in relation to practitioner types, stem cell therapies and their targets, stem cell-related interventions. Statements about stem cell therapies relating to evidence of inefficacy, limited evidence of efficacy, general procedural risks, risks specific to the mode of therapy, regulatory status, experimental or unproven nature of therapy. Use of hype language (eg, language that exaggerates potential benefits).Results243 websites offered stem cell therapies. Many websites advertised stem cell transplantation from multiple sources, such as adipose-derived (112), bone marrow-derived (100), blood-derived (28), umbilical cord-derived (26) and others. Plant stem cell-based treatments and products (20) were also advertised. Purposes for and targets of treatment included pain, physical injury, a wide range of diseases and illnesses, cosmetic concerns, non-cosmetic ageing, sexual enhancement and others. Medical doctors (130), chiropractors (53) and naturopaths (44) commonly work in the clinics we found to be offering stem cell therapies. Few clinic websites advertising stem cell therapies included important additional information, including statements about evidence of inefficacy (present on only 12.76% of websites), statements about limited evidence of efficacy (18.93%), statements of general risks (24.69%), statements of risks specific to the mode(s) of therapy (5.76%), statements as to the regulatory status of the therapies (30.86%) and statements that the therapy is experimental or unproven (33.33%). Hype language was noted (31.69%).ConclusionsStem cell therapies and related interventions are marketed for a wide breadth of conditions and are being offered by complementary and alternative practitioners, often in conjunction with medical doctors. Consumer protection and truth-in-advertising regulation could play important roles in addressing misleading marketing practices in this area.


Author(s):  
Qi Zhang ◽  
Xin-xing Wan ◽  
Xi-min Hu ◽  
Wen-juan Zhao ◽  
Xiao-xia Ban ◽  
...  

Stem cell therapies have shown promising therapeutic effects in restoring damaged tissue and promoting functional repair in a wide range of human diseases. Generations of insulin-producing cells and pancreatic progenitors from stem cells are potential therapeutic methods for treating diabetes and diabetes-related diseases. However, accumulated evidence has demonstrated that multiple types of programmed cell death (PCD) existed in stem cells post-transplantation and compromise their therapeutic efficiency, including apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis. Understanding the molecular mechanisms in PCD during stem cell transplantation and targeting cell death signaling pathways are vital to successful stem cell therapies. In this review, we highlight the research advances in PCD mechanisms that guide the development of multiple strategies to prevent the loss of stem cells and discuss promising implications for improving stem cell therapy in diabetes and diabetes-related diseases.


2017 ◽  
Vol 34 ◽  
pp. 39-50 ◽  
Author(s):  
Yuan Wang ◽  
Xunming Ji ◽  
Rehana K. Leak ◽  
Fenghua Chen ◽  
Guodong Cao

2014 ◽  
Vol 62 (S 01) ◽  
Author(s):  
M. Arar ◽  
A. Rotärmel ◽  
A.-K. Knoefel ◽  
H. Baraki ◽  
I. Kutschka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document